Correlation between Plasma Carnitine, Muscle Carnitine and Glycogen Levels in Maintenance Hemodialysis Patients

Alicja Dębska‐Ślizień(Gdańsk Medical University), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), J. Prajs(Gdańsk Medical University), D Kunicka(Gdańsk Medical University), Sylwia Małgorzewicz(Gdańsk Medical University), Aleksandra Kawecka(Gdańsk Medical University), Zbigniew Zdrojewski(Gdańsk Medical University), Wieslawa Lysiak‐Szydlowska(Gdańsk Medical University), J Lipinski, Klaudiusz Wojnarowski(Gdańsk Medical University)
The International Journal of Artificial Organs
February 1, 2000
10.1177/039139880002300205
Cited by 39

Related Papers

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2020|482
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
|Journal of Clinical Oncology|2010|401